

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.

PATENT COOPERATION TREATY

PCT

NOTIFICATION OF ELECTION

(PCT Rule 61.2)

From the INTERNATIONAL BUREAU

To:

Assistant Commissioner for Patents
United States Patent and Trademark
Office
Box PCT
Washington, D.C. 20231
ÉTATS-UNIS D'AMÉRIQUE

in its capacity as elected Office

Date of mailing (day/month/year) 02 March 2000 (02.03.00)	
International application No. PCT/US99/12906	Applicant's or agent's file reference PF-0531 PCT
International filing date (day/month/year) 08 June 1999 (08.06.99)	Priority date (day/month/year) 08 June 1998 (08.06.98)
Applicant BANDMAN, Olga et al	

1. The designated Office is hereby notified of its election made:

☒ in the demand filed with the International Preliminary Examining Authority on:

21 December 1999 (21.12.99)

☐ in a notice effecting later election filed with the International Bureau on:2. The election ☒ was☐ was not

made before the expiration of 19 months from the priority date or, where Rule 32 applies, within the time limit under Rule 32.2(b).

The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland	Authorized officer F. Baechler
Facsimile No.: (41-22) 740.14.35	Telephone No.: (41-22) 338.83.38



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C12N 15/12, 5/10, 1/21, C07K 14/47, 16/18, C12Q 1/68, A61K 38/17	A3	(11) International Publication Number: WO 99/64593 (43) International Publication Date: 16 December 1999 (16.12.99)
(21) International Application Number: PCT/US99/12906 (22) International Filing Date: 8 June 1999 (08.06.99) (30) Priority Data: 60/088,695 8 June 1998 (08.06.98) US (63) Related by Continuation (CON) or Continuation-in-Part (CIP) to Earlier Application US 60/088,695 (CIP) Filed on 8 June 1998 (08.06.98) (71) Applicant (for all designated States except US): INCYTE PHARMACEUTICALS, INC. [US/US]; 3174 Porter Drive, Palo Alto, CA 94304 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): BANDMAN, Olga [US/US]; 366 Anna Avenue, Mountain View, CA 94043 (US). LAL, Preeti [IN/US]; 2382 Lass Drive, Santa Clara, CA 95054 (US). TANG, Y., Tom [CN/US]; 4230 Ranwick Court, San Jose, CA 95118 (US). CORLEY, Neil, C. [US/US]; 1240 Dale Avenue #30, Mountain View, CA 94040 (US). GUEGLER, Karl, J. [CH/US]; 1048 Oakland Avenue, Menlo Park, CA 94025 (US). BAUGHN, Mariah,		R. [US/US]; 14244 Santiago Road, San Leandro, CA 94577 (US). PATTERSON, Chandra [US/US]; 490 Sherwood Way #1, Menlo Park, CA 94025 (US). (74) Agents: BILLINGS, Lucy, J. et al.; Incyte Pharmaceuticals, Inc., 3174 Porter Drive, Palo Alto, CA 94304 (US). (81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> (88) Date of publication of the international search report: 30 March 2000 (30.03.00)
(54) Title: CELL CYCLE REGULATION PROTEINS (57) Abstract <p>The invention provides a human cell cycle regulation proteins (CECRP) and polynucleotides which identify and encode CECRP. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating or preventing disorders associated with expression of CECRP.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 99/12906

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C12N15/12 C12N5/10 C12N1/21 C07K14/47 C07K16/18
C12Q1/68 A61K38/17

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C12N C07K C12Q A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>DATABASE EMBEST20 [Online] E.M.B.L. Databases Accession Number: AA280100, 3 April 1997 (1997-04-03) NCI-CGAP: "Homo sapiens cDNA clone IMAGE:705030 5' similar to TR:G487787 G487787 ZINC FINGER PROTEIN ZNF140." XP002118250 98.9% identity in 531bp overlap with SeqIdNo.6 abstract</p> <p style="text-align: center;">---</p> <p style="text-align: center;">-/--</p>	1-12

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *Z* document member of the same patent family

Date of the actual completion of the international search

8 October 1999

Date of mailing of the international search report

13. 01. 00

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Lonnoy, 0

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 99/12906

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	DATABASE EMBEST27 [Online] E.M.B.L. Databases Accession Number: AA307127, 18 April 1997 (1997-04-18) ADAMS M ET AL: "Homo sapiens cDNA 5' end similar to similar to zinc finger protein family" XP002118251 98.9% identity in 455bp overlap with SeqIdNo.6 abstract	1-12
X	--- DATABASE EMSET 25 [Online] E.M.B.L. databases Accession Number: AA148046, 15 December 1996 (1996-12-15) HILLIER L ET AL: "Homo sapiens cDNA clone 590442 5' similar to TR:G577019 G577019 PROCKR2" XP002118252 97.0% identity in 603bp overlap with SeqIdNo.6 abstract	3-9
A	--- TURNER C ET AL: "Blimp-1, a novel zinc finger-containing protein that can drive the maturation of B lymphocytes into immunoglobulin-secreting cells" CELL, vol. 77, no. 2, 22 April 1997 (1997-04-22), pages 297-306, XP002118249 cited in the application	
A	--- WO 95 28483 A (COLD SPRING HARBOR LAB) 26 October 1995 (1995-10-26) -----	

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 99/ 12906

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
Remark: Although claims 17-21, as far as in vivo methods are concerned, are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☒ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
see FURTHER INFORMATION sheet
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

B x II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

1-23 (all partially)

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

1. Claims: 1-23 (all partially)

A substantially purified polypeptide comprising sequence according SeqIdNo.1 or a polypeptide at least 90% identical to SeqIdNo.1 or a part thereof; a substantially purified polynucleotide coding for the above polypeptide or comprising the sequence of SeqIdNo.6 or a variant thereof with at least 90% identity; An expression vector and a host cell comprising the above sequence and a method for producing the same; Antibodies, agonists and antagonists against the above polypeptide and a pharmaceutical composition containing the polypeptide; Methods to treat or prevent cancer or immune disorders using above polypeptide or antagonist thereof; Method for detecting polynucleotides encoding the polypeptide.

2. Claims: 1-23 (all partially)

As for subject 1, but respectively relating to SeqIdNo.2 and SeqIdNo.7

3. Claims: 1-23 (all partially)

As for subject 1, but respectively relating to SeqIdNo.3 and SeqIdNo.8

4. Claims: 1-23 (all partially)

As for subject 1, but respectively relating to SeqIdNo.4 and SeqIdNo.9

5. Claims: 1-23 (all partially)

As for subject 1, but respectively relating to SeqIdNo.5 and SeqIdNo.10

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Claims 15, 16, 18, 20, respectively relating to an agonist/antagonist of the polypeptide of claim 1, and to therapeutic uses of said antagonist, could not be searched completely as the corresponding subject-matters were insufficiently disclosed.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 99/12906

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9528483 A	26-10-1995	US 5889169 A	30-03-1999
		US 5962316 A	05-10-1999
		AU 703908 B	01-04-1999
		AU 2384595 A	10-11-1995
		CA 2186639 A	15-10-1995
		EP 0755445 A	29-01-1997
		JP 9512424 T	16-12-1999
		US 5919997 A	06-07-1999
		US 5824315 A	20-10-1998
		US 5968821 A	19-10-1999

PCT

INTERNATIONAL SEARCH REPORT

(PCT Article 18 and Rules 43 and 44)

Applicant's or agent's file reference PF-0531 PCT	FOR FURTHER ACTION see Notification of Transmittal of International Search Report (Form PCT/ISA/220) as well as, where applicable, item 5 below.	
International application No. PCT/US 99/ 12906	International filing date (day/month/year) 08/06/1999	(Earliest) Priority Date (day/month/year) 08/06/1998
Applicant INCYTE PHARMACEUTICALS, INC. et al.		

This International Search Report has been prepared by this International Searching Authority and is transmitted to the applicant according to Article 18. A copy is being transmitted to the International Bureau.

This International Search Report consists of a total of 6 sheets.

☐

It is also accompanied by a copy of each prior art document cited in this report.

1. Basis of the report

- a. With regard to the **language**, the international search was carried out on the basis of the international application in the language in which it was filed, unless otherwise indicated under this item.

☐

the international search was carried out on the basis of a translation of the international application furnished to this Authority (Rule 23.1(b)).

- b. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, the international search was carried out on the basis of the sequence listing :

☒

contained in the international application in written form.

☒

filed together with the international application in computer readable form.

☐

furnished subsequently to this Authority in written form.

☐

furnished subsequently to this Authority in computer readable form.

☐

the statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.

☐

the statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished

2. ☒ **Certain claims were found unsearchable** (See Box I).

3. ☒ **Unity of invention is lacking** (see Box II).

4. With regard to the title,

☒

the text is approved as submitted by the applicant.

☐

the text has been established by this Authority to read as follows:

5. With regard to the abstract,

☒

the text is approved as submitted by the applicant.

☐

the text has been established, according to Rule 38.2(b), by this Authority as it appears in Box III. The applicant may, within one month from the date of mailing of this international search report, submit comments to this Authority.

6. The figure of the drawings to be published with the abstract is Figure No.

☐

as suggested by the applicant.

☐

because the applicant failed to suggest a figure.

☐

because this figure better characterizes the invention.

☐

None of the figures.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 99/ 12906

B x I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
Remark: Although claims 17-21, as far as in vivo methods are concerned, are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☒ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
see FURTHER INFORMATION sheet
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

B x II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

1-23 (all partially)

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

1. Claims: 1-23 (all partially)

A substantially purified polypeptide comprising sequence according SeqIdNo.1 or a polypeptide at least 90% identical to SeqIdNo.1 or a part thereof; a substantially purified polynucleotide coding for the above polypeptide or comprising the sequence of SeqIdNo.6 or a variant thereof with at least 90% identity; An expression vector and a host cell comprising the above sequence and a method for producing the same; Antibodies, agonists and antagonists against the above polypeptide and a pharmaceutical composition containing the polypeptide; Methods to treat or prevent cancer or immune disorders using above polypeptide or antagonist thereof; Method for detecting polynucleotides encoding the polypeptide.

2. Claims: 1-23 (all partially)

As for subject 1, but respectively relating to SeqIdNo.2 and SeqIdNo.7

3. Claims: 1-23 (all partially)

As for subject 1, but respectively relating to SeqIdNo.3 and SeqIdNo.8

4. Claims: 1-23 (all partially)

As for subject 1, but respectively relating to SeqIdNo.4 and SeqIdNo.9

5. Claims: 1-23 (all partially)

As for subject 1, but respectively relating to SeqIdNo.5 and SeqIdNo.10

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Claims 15, 16, 18, 20, respectively relating to an agonist/antagonist of the polypeptide of claim 1, and to therapeutic uses of said antagonist, could not be searched completely as the corresponding subject-matters were insufficiently disclosed.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

INTERNATIONAL SEARCH REPORT

National Application No

PCT/US 99/12906

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C12N15/12 C12N5/10 C12N1/21 C07K14/47 C07K16/18
C12Q1/68 A61K38/17

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C12N C07K C12Q A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>DATABASE EMBEST20 [Online] E.M.B.L. Databases Accession Number: AA280100, 3 April 1997 (1997-04-03) NCI-CGAP: "Homo sapiens cDNA clone IMAGE:705030 5' similar to TR:G487787 G487787 ZINC FINGER PROTEIN ZNF140." XP002118250 98.9% identity in 531bp overlap with SeqIdNo.6 abstract</p> <p style="text-align: center;">---</p> <p style="text-align: center;">-/--</p>	1-12



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- * & * document member of the same patent family

Date of the actual completion of the international search

8 October 1999

Date of mailing of the international search report

13. 01. 00

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Lonnoy, 0

INTERNATIONAL SEARCH REPORT

International Application No

T/US 99/12906

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>DATABASE EMBEST27 [Online] E.M.B.L. Databases Accession Number: AA307127, 18 April 1997 (1997-04-18) ADAMS M ET AL: "Homo sapiens cDNA 5' end similar to similar to zinc finger protein family" XP002118251 98.9% identity in 455bp overlap with SeqIdNo.6 abstract</p>	1-12
X	<p>--- DATABASE EMSET 25 [Online] E.M.B.L. databases Accession Number: AA148046, 15 December 1996 (1996-12-15) HILLIER L ET AL: "Homo sapiens cDNA clone 590442 5' similar to TR:G577019 G577019 PROCKR2" XP002118252 97.0% identity in 603bp overlap with SeqIdNo.6 abstract</p>	3-9
A	<p>--- TURNER C ET AL: "Blimp-1, a novel zinc finger-containing protein that can drive the maturation of B lymphocytes into immunoglobulin-secreting cells" CELL, vol. 77, no. 2, 22 April 1997 (1997-04-22), pages 297-306, XP002118249 cited in the application</p>	
A	<p>--- WO 95 28483 A (COLD SPRING HARBOR LAB) 26 October 1995 (1995-10-26) -----</p>	

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 99/12906

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9528483 A	26-10-1995	US 5889169 A	30-03-1999
		US 5962316 A	05-10-1999
		AU 703908 B	01-04-1999
		AU 2384595 A	10-11-1995
		CA 2186639 A	15-10-1995
		EP 0755445 A	29-01-1997
		JP 9512424 T	16-12-1999
		US 5919997 A	06-07-1999
		US 5824315 A	20-10-1998
		US 5968821 A	19-10-1999
